A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Trial details
- Registry ID
- NCT06072781
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as defactinib (VS-6063)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781 | VSTM | Phase 3 | Recruiting | 2028-10-15Estimated |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221 | VSTM | Phase 1, Phase 2 | Recruiting | 2028-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |